Dr Reddy's Laboratories has released its 2007-Sustainability Report, prepared in accordance with Global reporting initiative, according to G V Prasad, vice chairman and CEO, Dr Reddy's Labs.

Releasing the report at a press conference here on Wednesday, Prasad enumerated eleven values aimed at delivering "Sustained value with equal emphasis on people". He said "Dr Reddy's is the first pharmaceutical company and among the very few Indian companies to have initiated this process of documenting its activities towards sustainable development on three fronts." The fronts were "Economic, social and environment," he pointed out.

Dr Reddy, he observed, had adopted a triple bottom line approach to sustainability thinking which involved creating multiple sustainability opportunities at three key levels. They were "people, profit and planet." The concept "people" meant "customers, employees, patients, suppliers, community, investors and shareholders." The profit meant "execution excellence, lean manufacturing and simplicity". And the planet meant "environment protection," he elaborated.

Saying that "Our vision is to become a discovery-led global pharmaceutical company," Prasad elucidated that the "Company committed significant investments in infrastructure and facilities for almost all its business to support potential revenue scale up in the near future." Focus was also on rapid scale-up of the Active Pharma Ingredients (API) pipeline, branded finished dosage and geris finished dosage business. They would not only enhance value for our stakeholders but also generate surpluses or reinvestment in our innovation-led business.

Betapharm, Germany's fourth largest generics pharmaceutical company and Roche's API manufacturing site in Mexico had been performing well and they were well integrated into the company. The manufacturing plants, seven chemical Technical operations units that produce APIs and six Formulations Technical Operations units for finished dosages, were benchmarked with demanding standards from international regulatory bodies - the US FDA, UK MHRA, MCC and MCA, he added.